The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA. Cancer J. Clin. 64(1), 9–29 (2014).
  MedlineGoogle Scholar
• 2 Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57–70 (2000).
  Medline CASGoogle Scholar
• 3 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011).•• Excellent review of the hallmarks of tumorigenesis and provide the macroscopic outline of cancer.
  Medline CASGoogle Scholar
• 4 Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 26(22), 3279–3290 (2007).
  Medline CASGoogle Scholar
• 5 Yang SH, Sharrocks AD, Whitmarsh AJ. MAP kinase signalling cascades and transcriptional regulation. Gene 513(1), 1–13 (2013).
  Medline CASGoogle Scholar
• 6 Meister M, Tomasovic A, Banning A, Tikkanen R. Mitogen-activated protein (MAP) kinase scaffolding proteins: a recount. Int. J. Mol. Sci. 14(3), 4854–4884 (2013).
  Medline CASGoogle Scholar
• 7 Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol. Rev. 92(2), 689–737 (2012).
  Medline CASGoogle Scholar
• 8 Jones DTW, Gronych J, Lichter P, Witt O, Pfister SM. MAPK pathway activation in pilocytic astrocytoma. Cell. Mol. Life Sci. 69(11), 1799–1811 (2012).
  Medline CASGoogle Scholar
• 9 Lowenstein EJ, Daly RJ, Batzer AG et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 70(3), 431–442 (1992).
  Medline CASGoogle Scholar
• 10 Chin L, Tam A, Pomerantz J et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400(6743), 468–472 (1999).
  Medline CASGoogle Scholar
• 11 Van Aelst L, Barr M, Marcus S, Polverino A, Wigler M. Complex formation between RAS and RAF and other protein kinases. Proc. Natl Acad. Sci. USA 90(13), 6213–6217 (1993).
  Medline CASGoogle Scholar
• 12 Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24(1), 21–44 (2006).
  Medline CASGoogle Scholar
• 13 Mackesy DZ, Goalstone ML. ERK5: novel mediator of insulin and TNF‐stimulated VCAM‐1 expression in vascular cells. J. Diabetes 6(6), 595–602 (2014).
  Medline CASGoogle Scholar
• 14 Zhou Y, Tanaka T, Sugiyama N et al. p38-Mediated phosphorylation of Eps15 endocytic adaptor protein. FEBS Lett. 588(1), 131–137 (2014).
  Medline CASGoogle Scholar
• 15 Sanchez-Fernandez G, Cabezudo S, Garcia-Hoz C, Tobin AB, Mayor F Jr, Ribas C. ERK5 activation by Gq-coupled muscarinic receptors is independent of receptor internalization and beta-arrestin recruitment. PLoS One 8(12), e84174 (2013).
  MedlineGoogle Scholar
• 16 Zhang T, Inesta-Vaquera F, Niepel M et al. Discovery of potent and selective covalent inhibitors of JNK. Chem. Biol. 19(1), 140–154 (2012).
  Medline CASGoogle Scholar
• 17 Osborne JK, Zaganjor E, Cobb MH. Signal control through Raf: in sickness and in health. Cell Res. 22(1), 14–22 (2012).
  Medline CASGoogle Scholar
• 18 Shugar D, Fabbro D. Inhibitors of protein kinases. Biochim. Biophys. Acta 1834(7), 1269–1270 (2013).
  Medline CASGoogle Scholar
• 19 Neuzillet C, Tijeras-Raballand A, De Mestier L, Cros J, Faivre S, Raymond E. MEK in cancer and cancer therapy. Pharmacol. Ther. 141(2), 160–171 (2014).
  Medline CASGoogle Scholar
• 20 Taketomi A, Shirabe K, Muto J et al. A rare point mutation in the Ras oncogene in hepatocellular carcinoma. Surg. Today 43(3), 289–292 (2013).
  Medline CASGoogle Scholar
• 21 Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 49(17), 4682–4689 (1989).
  Medline CASGoogle Scholar
• 22 Grabocka E, Pylayeva-Gupta Y, Jones MJ et al. Wild-Type H-and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell 25(2), 243–256 (2014).
  Medline CASGoogle Scholar
• 23 Huang TG, Karsy M, Zhuge J, Zhong MH, Liu DL. B-Raf and the inhibitors: from bench to bedside. J. Hematol. Oncol. 6(1), 30 (2013).• Important paper elucidate the drug resistance of BRAF inhibitors.
  Medline CASGoogle Scholar
• 24 Rahman MA, Salajegheh A, Smith RA, Lam AK. B-Raf mutation: a key player in molecular biology of cancer. Exp. Mol. Pathol. 95(3), 336–342 (2013).
  Medline CASGoogle Scholar
• 25 Hatzivassiliou G, Song K, Yen I et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464(7287), 431–435 (2010).
  Medline CASGoogle Scholar
• 26 Guo W, Hao B, Wang Q, Lu Y, Yue J. Requirement of B-Raf, C-Raf, and A-Raf for the growth and survival of mouse embryonic stem cells. Exp. Cell Res. 319(18), 2801–2811 (2013).
  Medline CASGoogle Scholar
• 27 Buonato JM, Lazzara MJ. ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition. Cancer Res. 74(1), 309–319 (2014).
  Medline CASGoogle Scholar
• 28 Stuart DD, Sellers WR. Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer. Nat. Med. 19(5), 538–540 (2013).
  Medline CASGoogle Scholar
• 29 Kim KB, Kefford R, Pavlick AC et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 31(4), 482–489 (2013).
  Medline CASGoogle Scholar
• 30 Sievert AJ, Lang SS, Boucher KL et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc. Natl Acad. Sci. USA 110(15), 5957–5962 (2013).
  Medline CASGoogle Scholar
• 31 Villanueva J, Infante JR, Krepler C et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep. 4(6), 1090–1099 (2013).
  Medline CASGoogle Scholar
• 32 Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N. Engl. J. Med. 364(8), 772–774 (2011).
  Medline CASGoogle Scholar
• 33 Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809–819 (2010).
  Medline CASGoogle Scholar
• 34 Morris EJ, Jha S, Restaino CR et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 3(7), 742–750 (2013).• Key paper report biological efficay of novel ERK inhibitors, and especially shown that ERK inhibitors could overcome acquired resistance of up-stream inhibitors.
  Medline CASGoogle Scholar
• 35 Nissan MH, Rosen N, Solit DB. ERK pathway inhibitors: how low should we go? Cancer Discov. 3(7), 719–721 (2013).
  Medline CASGoogle Scholar
• 36 Hatzivassiliou G, Liu B, O'brien C et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol. Cancer Ther. 11(5), 1143–1154 (2012).
  Medline CASGoogle Scholar
• 37 Roskoski Jr R. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol. Res. 66(2), 105–143 (2012).
  Medline CASGoogle Scholar
• 38 Luke JJ, Hodi FS. Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist 18(6), 717–725 (2013).
  Medline CASGoogle Scholar
• 39 Van Allen EM, Wagle N, Sucker A et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4(1), 94–109 (2014).
  Medline CASGoogle Scholar
• 40 Bolick SCE, Landowski TH, Boulware D et al. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia 17(2), 451–457 (2003).
  Medline CASGoogle Scholar
• 41 Kloog Y, Cox AD. RAS inhibitors: potential for cancer therapeutics. Mol. Med. Today 6(10), 398–402 (2000).
  Medline CASGoogle Scholar
• 42 Blum R, Elkon R, Yaari S et al. Gene expression signature of human cancer cell lines treated with the Ras inhibitor Salirasib (S-Farnesylthiosalicylic Acid). Cancer Res. 67(7), 3320–3328 (2007).
  Medline CASGoogle Scholar
• 43 Mark GE, Rapp UR. Primary structure of v-raf: relatedness to the src family of oncogenes. Science 224(4646), 285–289 (1984).
  Medline CASGoogle Scholar
• 44 Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949–954 (2002).
  Medline CASGoogle Scholar
• 45 Hauschild A, Agarwala SS, Trefzer U et al. Results of a Phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable Stage III or Stage IV melanoma. J. Clin. Oncol. 27(17), 2823–2830 (2009).
  Medline CASGoogle Scholar
• 46 Kudo M, Ueshima K. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology 78(Suppl.1), 154–166 (2010).
  Medline CASGoogle Scholar
• 47 Joseph EW, Pratilas CA, Poulikakos PI et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl Acad. Sci. USA 107(33), 14903–14908 (2010).
  Medline CASGoogle Scholar
• 48 Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507–2516 (2011).
  Medline CASGoogle Scholar
• 49 Ott PA, Henry T, Baranda SJ et al. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol. Immunother. 62(4), 811–822 (2013).
  Medline CASGoogle Scholar
• 50 Trunzer K, Pavlick AC, Schuchter L et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 31(14), 1767–1774 (2013).
  Medline CASGoogle Scholar
• 51 Wagle N, Emery C, Berger MF et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29(22), 3085–3096 (2011).
  Medline CASGoogle Scholar
• 52 Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a Phase 1 dose-escalation trial. Lancet 379(9829), 1893–1901 (2012).
  Medline CASGoogle Scholar
• 53 Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13(11), 1087–1095 (2012).
  Medline CASGoogle Scholar
• 54 Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839), 358–365 (2012).
  Medline CASGoogle Scholar
• 55 Garcia-Gomez A, Ocio EM, Pandiella A, San Miguel JF, Garayoa M. RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest. New Drugs 31(1), 200–205 (2013).
  Medline CASGoogle Scholar
• 56 Hoeflich KP, Herter S, Tien J et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 69(7), 3042–3051 (2009).
  Medline CASGoogle Scholar
• 57 Garber K. Melanoma combination therapies ward off tumor resistance. Nat. Biotechnol. 31(8), 666–668 (2013).
  Medline CASGoogle Scholar
• 58 Roskoski Jr R. MEK1/2 dual-specificity protein kinases: structure and regulation. Biochem. Biophys. Res. Commun. 417(1), 5–10 (2012).
  Medline CASGoogle Scholar
• 59 Wagle N, Van Allen EM, Treacy DJ et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 4(1), 61–68 (2014).
  Medline CASGoogle Scholar
• 60 Wallace EM, Lyssikatos JP, Yeh T, Winkler JD, Koch K. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr. Top. Med. Chem. 5(2), 215–229 (2005).
  Medline CASGoogle Scholar
• 61 Martin-Liberal J, Lagares-Tena L, Larkin J. Prospects for MEK inhibitors for treating cancer. Expert Opin. Drug Saf. 13(4), 483–495 (2014).•• Important review outline the future research and application of MEK inhibitors.
  Medline CASGoogle Scholar
• 62 Ge X, Fu Y, Meadows GG. U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells. Cancer Lett. 179(2), 133–140 (2002).
  Medline CASGoogle Scholar
• 63 Mccubrey JA, Steelman LS, Abrams SL et al. Emerging MEK inhibitors. Expert Opin. Emerg. Drugs 15(2), 203–223 (2010).
  Medline CASGoogle Scholar
• 64 Rinehart J, Adjei AA, Lorusso PM et al. Multicenter Phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22(22), 4456–4462 (2004).
  Medline CASGoogle Scholar
• 65 Lorusso PM, Krishnamurthi SS, Rinehart JJ et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin. Cancer Res. 16(6), 1924–1937 (2010).
  Medline CASGoogle Scholar
• 66 Haura EB, Ricart AD, Larson TG et al. A Phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 16(8), 2450–2457 (2010).
  Medline CASGoogle Scholar
• 67 Martinelli E, Troiani T, D'aiuto E et al. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells. Int. J. Cancer 133(9), 2089–2101 (2013).
  Medline CASGoogle Scholar
• 68 Wong H, Vernillet L, Peterson A et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic–pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin. Cancer Res. 18(11), 3090–3099 (2012).
  Medline CASGoogle Scholar
• 69 Gilmartin AG, Bleam MR, Groy A et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17(5), 989–1000 (2011).
  Medline CASGoogle Scholar
• 70 Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int. J. Oncol. 39(1), 23–31 (2011).
  Medline CASGoogle Scholar
• 71 Infante JR, Fecher LA, Falchook GS et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 13(8), 773–781 (2012).
  Medline CASGoogle Scholar
• 72 Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367(2), 107–114 (2012).
  Medline CASGoogle Scholar
• 73 Wallace EM, Lyssikatos J, Blake JF et al. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones. J. Med. Chem. 49(2), 441–444 (2006).
  Medline CASGoogle Scholar
• 74 Davies BR, Logie A, Mckay JS et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol. Cancer Ther. 6(8), 2209–2219 (2007).
  Medline CASGoogle Scholar
• 75 Yeh TC, Marsh V, Bernat BA et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 13(5), 1576–1583 (2007).
  Medline CASGoogle Scholar
• 76 Little AS, Balmanno K, Sale MJ et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci. Signal 4(166), ra17 (2011).
  MedlineGoogle Scholar
• 77 Bid HK, Kibler A, Phelps DA et al. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor Selumetinib (AZD6244) in an in vivo model of childhood Astrocytoma. Clin. Cancer Res. 19(24), 6716–6729 (2013).
  Medline CASGoogle Scholar
• 78 Adjei AA, Cohen RB, Franklin W et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26(13), 2139–2146 (2008).
  Medline CASGoogle Scholar
• 79 Bennouna J, Lang I, Valladares-Ayerbes M et al. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest. New Drugs 29(5), 1021–1028 (2011).
  Medline CASGoogle Scholar
• 80 Bodoky G, Timcheva C, Spigel DR et al. A Phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest. New Drugs 30(3), 1216–1223 (2012).
  Medline CASGoogle Scholar
• 81 Hainsworth JD, Cebotaru CL, Kanarev V et al. A Phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J. Thorac. Oncol. 5(10), 1630–1636 (2010).
  MedlineGoogle Scholar
• 82 Kirkwood JM, Bastholt L, Robert C et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 18(2), 555–567 (2012).
  Medline CASGoogle Scholar
• 83 O'neil BH, Goff LW, Kauh JS et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 29(17), 2350–2356 (2011).
  MedlineGoogle Scholar
• 84 Kalia M. Personalized oncology: recent advances and future challenges. Metabolism 62(Suppl.1), s11–s14 (2013).
  Medline CASGoogle Scholar
• 85 Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur. J. Cancer 49(6), 1297–1304 (2013).
  Medline CASGoogle Scholar
• 86 Sos ML, Levin RS, Gordan JD et al. Oncogene mimicry as a mechanism of primary resistance to BRAF Inhibitors. Cell Rep. 8(4), 1037–1048 (2014).
  Medline CASGoogle Scholar
• 87 Sheppard KE, Cullinane C, Hannan KM et al. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur. J. Cancer 49(18), 3936–3944 (2013).
  Medline CASGoogle Scholar
• 88 Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 16(3), 368–377 (2009).
  Medline CASGoogle Scholar
• 89 Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int. J. Cancer 125(10), 2332–2341 (2009).
  Medline CASGoogle Scholar
• 90 Lui VW, Hedberg ML, Li H et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 3(7), 761–769 (2013).
  Medline CASGoogle Scholar
• 91 Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464(7287), 427–430 (2010).
  Medline CASGoogle Scholar
• 92 Basile KJ, Abel EV, Dadpey N, Hartsough EJ, Fortina P, Aplin AE. In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors. Cancer Res. 73(23), 7101–7110 (2013).
  Medline CASGoogle Scholar
• 93 Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326), 973–977 (2010).
  Medline CASGoogle Scholar
• 94 Carlino MS, Todd JR, Gowrishankar K et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol. Oncol. 8(3), 544–554 (2014).
  Medline CASGoogle Scholar
• 95 Poulikakos PI, Persaud Y, Janakiraman M et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480(7377), 387–390 (2011).
  Medline CASGoogle Scholar
• 96 Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 73(15), 4840–4851 (2013).
  Medline CASGoogle Scholar
• 97 Emery CM, Vijayendran KG, Zipser MC et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl Acad. Sci. USA 106(48), 20411–20416 (2009).
  Medline CASGoogle Scholar
• 98 Wang H, Daouti S, Li WH et al. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Cancer Res. 71(16), 5535–5545 (2011).
  Medline CASGoogle Scholar
• 99 Fritsche-Guenther R, Witzel F, Sieber A et al. Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol. Syst. Biol. 7, 489 (2011).
  MedlineGoogle Scholar
• 100 Shin SY, Rath O, Choo SM et al. Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway. J. Cell Sci. 122(3), 425–435 (2009).
  Medline CASGoogle Scholar
• 101 Ritt DA, Monson DM, Specht SI, Morrison DK. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol. Cell Biol. 30(3), 806–819 (2010).
  Medline CASGoogle Scholar
• 102 Margarit SM, Sondermann H, Hall BE et al. Structural evidence for feedback activation by Ras. GTP of the Ras-specific nucleotide exchange factor SOS. Cell 112(5), 685–695 (2003).
  Medline CASGoogle Scholar
• 103 Huang CY, Tan TH. DUSPs, to MAP kinases and beyond. Cell Biosci. 2(1), 24 (2012).
  Medline CASGoogle Scholar
• 104 Lito P, Pratilas CA, Joseph EW et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22(5), 668–682 (2012).
  Medline CASGoogle Scholar
• 105 Whittaker SR, Theurillat JP, Van Allen E et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 3(3), 350–362 (2013).
  Medline CASGoogle Scholar
• 106 Su F, Bradley WD, Wang Q et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res. 72(4), 969–978 (2012).
  Medline CASGoogle Scholar
• 107 Aronov AM, Tang Q, Martinez-Botella G et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J. Med. Chem. 52(20), 6362–6368 (2009).
  Medline CASGoogle Scholar
• 108 Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin. Cancer Res. 11(1), 397–405 (2005).
  Medline CASGoogle Scholar
• 109 Turke AB, Zejnullahu K, Wu YL et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17(1), 77–88 (2010).
  Medline CASGoogle Scholar
• 110 Johannessen CM, Boehm JS, Kim SY et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326), 968–972 (2010).
  Medline CASGoogle Scholar
• 111 Shi H, Moriceau G, Kong X et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724 (2012).
  MedlineGoogle Scholar
• 112 Poulikakos PI, Solit DB. Resistance to MEK inhibitors: should we co-target upstream? Sci. Signal 4(166), pe16 (2011).
  MedlineGoogle Scholar
• 113 Robbins DJ, Zhen E, Owaki H et al. Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro. J. Biol. Chem. 268(7), 5097–5106 (1993).
  Medline CASGoogle Scholar
• 114 Hancock CN, Macias A, Lee EK, Yu SY, Mackerell AD Jr, Shapiro P. Identification of novel extracellular signal-regulated kinase docking domain inhibitors. J. Med. Chem. 48(14), 4586–4595 (2005).
  Medline CASGoogle Scholar
• 115 Sulzmaier FJ, Ramos JW. RSK isoforms in cancer cell invasion and metastasis. Cancer Res. 73(20), 6099–6105 (2013).
  Medline CASGoogle Scholar
• 116 Jameson KL, Mazur PK, Zehnder AM et al. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat. Med. 19(5), 626–630 (2013).
  Medline CASGoogle Scholar
• 117 Lefloch R, Pouyssegur J, Lenormand P. Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol. Cell Biol. 28(1), 511–527 (2008).
  Medline CASGoogle Scholar
• 118 Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J. Cell Sci. 117(20), 4619–4628 (2004).
  Medline CASGoogle Scholar
• 119 Vanhook AM. Proliferation or differentiation depends on ERK localization. 7(333), doi:10.1126/scisignal.2005658 (2014) (Epub ahead of print).
  Google Scholar
• 120 Radtke S, Milanovic M, Rosse C et al. ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines. J. Cell Sci. 126(11), 2381–2391 (2013).
  Medline CASGoogle Scholar
• 121 Marchi M, D'antoni A, Formentini I et al. The N-terminal domain of ERK1 accounts for the functional differences with ERK2. PLoS One 3(12), e3873 (2008).
  MedlineGoogle Scholar
• 122 Lefloch R, Pouyssegur J, Lenormand P. Total ERK1/2 activity regulates cell proliferation. Cell Cycle 8(5), 705–711 (2009).•• Important paper demonstrates the different function of ERK1 and ERK2.
  Medline CASGoogle Scholar
• 123 Guegan JP, Ezan F, Theret N, Langouet S, Baffet G. MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells. Carcinogenesis 34(1), 38–47 (2013).
  Medline CASGoogle Scholar
• 124 Shaul YD, Seger R. ERK1c regulates Golgi fragmentation during mitosis. J. Cell Biol. 172(6), 885–897 (2006).
  Medline CASGoogle Scholar
• 125 Cordero P, Ashley EA. Whole-genome sequencing in personalized therapeutics. Clin. Pharmacol. Ther. 91(6), 1001–1009 (2012).
  Medline CASGoogle Scholar
• 126 Fang W, Zhang J, Liang W et al. Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. J. Thor. Dis. 5(5), 585–592 (2013).
  MedlineGoogle Scholar
• 127 Qin J, Xin H, Nickoloff BJ. Specifically targeting ERK1 or ERK2 kills melanoma cells. J. Transl. Med. 10, 15 (2012).
  Medline CASGoogle Scholar
• 128 Gavrin LK, Saiah E. Approaches to discover non-ATP site kinase inhibitors. Med. Chem. Commun. 4(1), 41 (2013).•• Key paper elucidate the features of non-ATP inhibitors and how to design.
  CASGoogle Scholar
• 129 Yap JL, Worlikar S, Mackerell AD Jr, Shapiro P, Fletcher S. Small-molecule inhibitors of the ERK signaling pathway: towards novel anticancer therapeutics. Chem. Med. Chem. 6(1), 38–48 (2011).
  CASGoogle Scholar
• 130 Clydesdale GJ, Dandie GW, Muller HK. Ultraviolet light induced injury: immunological and inflammatory effects. Immunol. Cell Biol. 79(6), 547–568 (2001).
  Medline CASGoogle Scholar
• 131 Li J, Malakhova M, Mottamal M et al. Norathyriol suppresses skin cancers induced by solar ultraviolet radiation by targeting ERK kinases. Cancer Res. 72(1), 260–270 (2012).
  Medline CASGoogle Scholar
• 132 Bode AM, Dong Z. Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci. STKE 2003(167), RE2 (2003).
  MedlineGoogle Scholar
• 133 Ohori M, Kinoshita T, Okubo M et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem. Biophys. Res. Commun. 336(1), 357–363 (2005).
  Medline CASGoogle Scholar
• 134 Blake JF, Gaudino JJ, De Meese J et al. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2. Bioorg. Med. Chem. Lett. 24(12), 2635–2639 (2014).
  Medline CASGoogle Scholar
• 135 Gerlach MP, Seipelt I, Mueller G et al. Novel pyrido[2,3-b]pyrazines as orally active ERK inhibitors. Presented at: 242nd ACS National Meeting & Exposition, Denver, CO, United States, 28 August – 1 September 2011, pagesMEDI-243.
  Google Scholar
• 136 Eralp Y, Derin D, Ozluk Y et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann. Oncol. 19(4), 669–674 (2008).
  Medline CASGoogle Scholar
• 137 The Broad Institute; Dana-Farber Cancer Institute: WO2013169858A1 (2013).
  Google Scholar
• 138 Clinical Trials. www.ClinicalTrials.gov.
  Google Scholar
• 139 Merck sharp & Dohme corp.: WO2013063214A1 (2013).
  Google Scholar
• 140 Schering corp.: WO2012087772A1 (2012).
  Google Scholar
• 141 Schering corp.: WO2012036997A1 (2012).
  Google Scholar
• 142 Schering corp.: WO2012030685A2 (2012).
  Google Scholar
• 143 Schering corp.: WO2012058127A2 (2012).
  Google Scholar
• 144 Merck sharp & Dohme corp.; Schering corp.: WO2011163330A1 (2011).
  Google Scholar
• 145 Schering corp.: WO2009105500A1 (2009).
  Google Scholar
• 146 Schering corp.; Merck sharp & Dohme corp.: US20090118284A1 (2009).
  Google Scholar
• 147 Nissan MH, Rosen N, Solit DB. ERK pathway inhibitors: how low should we go? Cancer Discov. 3(7), 719–721 (2013).
  Medline CASGoogle Scholar
• 148 Alderton GK. Therapy: combination and dosing schedule are key. Nat. Rev. Cancer 14(4), 215–215 (2014).
  Google Scholar
• 149 Kiel C, Serrano L. Challenges ahead in signal transduction: MAPK as an example. Curr. Opin. Biotechnol. 23(3), 305–314 (2012).
  Medline CASGoogle Scholar
• 150 Cohen P, Alessi DR. Kinase drug discovery-what's next in the field? ACS Chem. Biol. 8(1), 96–104 (2013).
  Medline CASGoogle Scholar